Actively Recruiting
Prospective Clinical Study of 18F-mFBG PET Imaging in Neuroblastoma to Evaluate Diagnostic Performance and Tumor Burden
Led by First Affiliated Hospital of Zhejiang University · Updated on 2025-08-08
200
Participants Needed
1
Research Sites
251 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the diagnostic performance and tumor burden detection of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with neuroblastoma, a cancer that highly expresses norepinephrine transporter (NET). Current imaging methods using 123/131I-MIBG have limitations such as low image resolution and lengthy procedures. The study aims to assess the safety, image quality, and diagnostic accuracy of 18F-MFBG PET, which can be performed quickly after injection and may improve detection of small lesions. In this study, patients with suspected or confirmed neuroblastoma will receive an intravenous dose of 5.55 MBq/kg of 18F-MFBG. After 60 minutes, participants will undergo PET/CT or PET/MR imaging to evaluate tumor presence and burden. The use of 18F-MFBG allows imaging to begin as soon as 0.5 hours after injection without special preparation, potentially offering a more convenient and effective diagnostic option. Participants will be involved in imaging and monitoring procedures lasting an average of 1.5 years to assess the diagnostic efficacy of 18F-MFBG PET. Researchers will evaluate safety profiles, scan image quality, and tumor burden measurements throughout the study period. This ongoing observation aims to provide comprehensive data on the performance of this imaging method in detecting neuroblastoma tumors.
CONDITIONS
Official Title
18F-mFBG PET Imaging in the Evaluation of Neuroblastoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 0 to 18 years old with a legal guardian
- Clinically suspected or confirmed neuroblastoma
- If under 8 years old or unable to write, guardian must understand and comply with study requirements
- If 8 years old or older and able to write, both patient and guardian must sign informed consent
You will not qualify if you...
- Severe primary diseases such as heart, brain, liver, kidney, or blood system diseases
- Ionizing radiation exposure exceeding 50 mSv in the past year outside this study
- Use of experimental drugs or devices within the past month
- Any condition deemed potentially harmful by the principal investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China, 310003
Actively Recruiting
Research Team
P
Peipei Wang, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here